Literature DB >> 7926095

Fertilization efficiency of morphologically abnormal spermatozoa in assisted reproduction is further impaired by antisperm antibodies on the male partner's sperm.

A A Acosta1, J P van der Merwe, G Doncel, T F Kruger, A Sayilgan, D R Franken, P Kolm.   

Abstract

OBJECTIVE: To investigate the influence of antisperm antibodies on the sperm surface on the outcome of IVF and GIFT.
DESIGN: Matched controlled retrospective review of two large series.
SETTING: Reproductive endocrine divisions of two level-three academic centers. PATIENTS: Twenty-nine male factor patients (38 IVF cycles) showing positive antisperm antibodies on the sperm by immunobead test treated by IVF at the Norfolk program and 56 similar patients (57 cycles) treated by GIFT at the Tygerberg program. Twenty-nine male factor patients (29 IVF cycles) with negative antisperm antibodies screening matched by wife's stimulation protocol and baseline semen analysis characteristics were used as controls in Norfolk; 56 GIFT patients (56 GIFT cycles) matched similarly were the Tygerberg controls. Study and control groups were divided according to sperm morphology pattern in normal, good, and poor prognosis subgroups for comparison. MAIN OUTCOME MEASURES: Fertilization rate of preovulatory oocytes used in IVF in Norfolk and of GIFT supernumerary preovulatory oocytes in Tygerberg; total and term pregnancy rates (PRs) and abortion rates.
RESULTS: Fertilization rate was significantly lower in the IVF (41.9% +/- 2.8%) as well as in the GIFT (26.8% +/- 3.8%) (mean +/- SE) study groups than in the respective control groups (73.1% +/- 3.9% and 61.8% +/- 3.9%). Total and term PRs in IVF per cycle (21.1% +/- 6.6%; 13.2% +/- 5.5%) and per transfer (23.5% +/- 7.4%; 14.7% +/- 6.1%), and in GIFT (25.0% +/- 5.8%; 19.6% +/- 5.3%) in the study groups were also lower when compared with their control counterparts (IVF per cycle: 62.1% +/- 6.2% and 41.4% +/- 6.0%; IVF per transfer: 41.9% +/- 2.0% and 27.9% +/- 1.9%; GIFT: 31.6% +/- 6.2% and 28.1% +/- 6.0%), but the difference did not reach statistical significance. Abortion rates were similar in the IVF study group (37.5% +/- 17.1%) and its control groups (39.9% +/- 11.5%). The abortion rate in the GIFT study group was 14.3% +/- 9.4%, and no abortions were recorded in the control group (not significant).
CONCLUSIONS: The presence of antisperm antibodies on the sperm surface per se impairs the outcome of assisted reproduction, mainly in terms of fertilization rate of preovulatory oocytes, and possibly in terms of total and term PRs. This holds true regardless of the impact of other semen parameters, particularly the morphology of the sperm within the semen sample.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926095     DOI: 10.1016/s0015-0282(16)57012-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

1.  Impact of fertilization history and semen parameters on ICSI outcome.

Authors:  R Mercan; S Oehninger; S J Muasher; J P Toner; J Mayer; S E Lanzendorf
Journal:  J Assist Reprod Genet       Date:  1998-01       Impact factor: 3.412

Review 2.  Antisperm antibodies and conception.

Authors:  L W Chamley; G N Clarke
Journal:  Semin Immunopathol       Date:  2007-06       Impact factor: 11.759

3.  In search for the general population's semen profile: the study of sperm parameters in partners of women with chronic anovulation.

Authors:  W Ombelet; E Bosmans; A Cox; M Janssen; G Mestdagh; M Nijs
Journal:  Facts Views Vis Obgyn       Date:  2009

4.  Success rates of in vitro fertilization versus intracytoplasmic sperm injection in men with serum anti-sperm antibodies: a consecutive cohort study.

Authors:  Shao-Ming Lu; Xiao Li; Shi-Li Wang; Xiao-Li Yang; Yan-Zhen Xu; Ling-Ling Huang; Jiao-Long Liu; Fei-Fei Cai; Zi-Jiang Chen
Journal:  Asian J Androl       Date:  2019 Sep-Oct       Impact factor: 3.285

Review 5.  Opportunities and Limits of Conventional IVF versus ICSI: It Is Time to Come off the Fence.

Authors:  Martina Balli; Anna Cecchele; Valerio Pisaturo; Sofia Makieva; Giorgia Carullo; Edgardo Somigliana; Alessio Paffoni; Paola Vigano'
Journal:  J Clin Med       Date:  2022-09-27       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.